AF
BMRN icon

Avanza Fonder’s BioMarin Pharmaceuticals BMRN Stock Holding History

Avanza Fonder’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,915
Closed -$1.43M – 442
2025
Q1 		$1.43M Buy
20,915
+4,759
+29% +$320K 0.05% 300
2024
Q4 		$1.06M Buy
+16,156
New +$1.08M 0.03% 330

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Avanza Fonder's BMRN Position: Q2 2025 in Review

Avanza Fonder sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 20,915 shares — an estimated $1.43M sold.

Avanza Fonder first reported a position in BMRN in Q4 2024 and held it in 2 quarters. The position peaked at $1.43M in Q1 2025. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • Avanza Fonder reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Avanza Fonder sold 20,915 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $1.43M.
  • Avanza Fonder first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Avanza Fonder's BioMarin Pharmaceuticals position peaked at $1.43M in Q1 2025.
  • 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Avanza Fonder's 13F filing for Q2 2025, filed 14 Jul 2025.